Bank of New York Mellon’s Climb Bio CLYM Stock Holding History

Bank of New York Mellon’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Buy	+123,658	New	+$1.28M	﹤0.01%	3077
2025 Q2	–	Sell	-64,914	Closed	-$79.2K	–	4300
2025 Q1	$79.2K	Hold	64,914	–	–	﹤0.01%	4026
2024 Q4	$117K	Hold	64,914	–	–	﹤0.01%	4017
2024 Q3	$330K	Buy	64,914 +46,069	+244%	+$326K	﹤0.01%	3716
2024 Q2	$134K	Buy	+18,845	New	+$125K	﹤0.01%	4003
2022 Q2	–	Sell	-13,893	Closed	-$117K	–	4716
2022 Q1	$117K	Sell	13,893 -162	-1%	-$1.51K	﹤0.01%	4379
2021 Q4	$147K	Buy	14,055 +847	+6%	+$12.6K	﹤0.01%	4343
2021 Q3	$237K	Buy	+13,208	New	+$273K	﹤0.01%	4134

Other funds holding CLYM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's CLYM Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Climb Bio (CLYM) in Q2 2026: 123,658 shares worth $1.61M. The stake represents ﹤0.01% of the portfolio and ranks #3077 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in CLYM as recently as Q1 2025.

Bank of New York Mellon first reported a position in CLYM in Q3 2021 and has held it in 8 quarters since. 24 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Bank of New York Mellon held 123,658 shares of Climb Bio worth $1.61M as of Q2 2026.
Climb Bio was a new Bank of New York Mellon position in Q2 2026.
Climb Bio made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3077 holding.
Bank of New York Mellon first reported a position in Climb Bio in Q3 2021 and has held it in 8 quarters since.
24 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.